SkinCare Physicians

Approvals begin to happen for 3 exciting treatment creams for psoriasis and eczema

Published on Sep 30th, 2021 by Jeffrey Sobell

Patient suffering from psoriasis on his backThere are three highly anticipated new topical creams for the treatment of psoriasis and eczema moving through the FDA clearance process as we write this blog.

Two new unique creams for psoriasis

For psoriasis, there has not been a novel non-steroidal topical medication approved in over twenty years. Thus, it is exciting that two unique creams have completed late-stage testing and are being reviewed by the FDA for potential authorization to prescribe within the next year.

  • Roflumilast cream 0.3% targets inflammation by inhibiting PDE-4*. In two large pivotal** studies, roughly 40% of patients were clear or almost clear of psoriasis after 8 weeks of daily application. In addition, most patients had clinically meaningful improvements in itch. Roflumilast cream 0.3% was well tolerated with a low rate of pain or reaction where the cream was applied.
  • Tapinarof cream 1%, the second topical, is a novel small molecule called TAMA***. Like roflumilast, once daily application of tapinarof cream demonstrated reproducible and exciting results with 40% of patients achieving clear or almost clear skin by week 12. The cream was well tolerated, with folliculitis (inflammation of the follicles) and contact dermatitis occurring in a minority of patients.

A unique topical medication for eczema

For eczema (atopic dermatitis), the FDA recently approved Opzelura® cream 1.5% in those aged 12 years and older with mild to moderate disease. This is the first topical agent belonging to a category of medications called JAK inhibitors. Opzelura® cream works by addressing the inflammation of eczema in a manner distinct from currently available options such as topical corticosteroids and other immunomodulatory creams including tacrolimus (Protopic®), pimecrolimus (Elidel®) and crisabarole (Eucrisa®). Two large pivotal** studies investigating Opzelura® cream in over 1200 atopic dermatitis subjects demonstrated impressive and consistent results. After 8 weeks of treatment, more than half of the patients showed clear or minimal signs of eczema. In addition, most patients had measurable improvements in itch. Although the cream was well tolerated, warnings commonly attributed to oral JAK inhibitors appear in the Opzelura® package insert. To help put this into context, we suggest coming in for a consultation with one of our skilled and trusted providers at SkinCare Physicians to discuss whether this new exciting treatment might be the right answer for you.

Although remembering their names might be a challenge, these new topical creams promise to bring relief to patients suffering from psoriasis and atopic dermatitis. Visit your dermatologist to find out if any of these therapies might be suited for you.

* PDE-4: Phosphodiesterase-4
** A pivotal study is a late-stage clinical trial seeking to demonstrate the efficacy and safety of a new drug in order to obtain its marketing approval by the FDA.
*** TAMA: Therapeutic aryl hydrocarbon receptor-modulating agent

Leave a Reply

Fields marked with * are required.

Back to top

Our Promise

Our team of renowned physicians and experienced support staff is committed to excellence in medical skin care and cosmetic procedures with a patient-centered focus for women and men in the greater Boston area and beyond.

Request a Consultation

Say goodbye to underarm sweat and odor.

miraDry® is a quick, non-surgical treatment providing immediate, long-lasting results with minimal downtime.

Learn More

miraDry model
miraDry Logo

Say goodbye to underarm sweat and odor.

miraDry® is a quick, non-surgical treatment providing immediate, long-lasting results with minimal downtime.

Learn More

Contact Us

The form below should not be used by patients to communicate clinical questions to SkinCare Physicians. It is not a patient portal. If your message is of an urgent, clinical or confidential nature, please call us instead at 1-617-383-8201. Please note that during the COVID-19 crisis, online telemedicine visits are available.


Please email me news and special offers

termsAccepted

Physician society logos

Chestnut Hill, MA (617) 731-1600

SkinCare Physicians®
1244 Boylston Street (Route 9)
Chestnut Hill, Massachusetts 02467

Phone: (617) 731-1600 Fax: (617) 731-1601

Medical Website Design & Marketing
by Etna Interactive

SkinCare Physicians®
1244 Boylston Street (Route 9)
Chestnut Hill, Massachusetts 02467

Phone: (617) 731-1600 Fax: (617) 731-1601

Medical Website Design & Marketing by Etna Interactive

The dermatologists and other medical professionals at SkinCare Physicians specialize in a wide range of dermatology treatments and services, including laser hair removal, laser skin treatment, hair transplant, eyelid surgery, body contouring, psoriasis, skin cancer, BOTOX® Cosmetic, fillers, and Thermage®. From their offices in Chestnut Hill, they serve Boston, Brookline, Cambridge, Newton and Wellesley.